Compare US Global Jets ETF (JETS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Summit Therapeutics Inc — how do they compare? US Global Jets ETF trades at $27.46 (market cap $878.48M), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 15.6× US Global Jets ETF's market cap, and Summit Therapeutics Inc is more actively traded (6,173,057 versus 4,465,925). Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 26 Days and Summit Therapeutics Inc for 16 Days on average.
| JETS | SMMT | |
|---|---|---|
Market Cap | $878.48M | $13.71B |
Volume | 4,465,925 | 6,173,057 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $26.38 |
52-Week Low | $23.64 | $12.43 |
Typical Hold Time | 26 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS ETF trades at $27.29, down 1.37% amid bearish technical signals with 17 sell indicators versus 4 buy signals. The airline-focused ETF faces headwinds from rising fuel costs and geopolitical tensions, while technical analysis shows strong resistance at $28 and support at $27. Recent news highlights underperformance compared to defense-focused aerospace ETFs and pressure from Middle East conflicts driving up airline operating expenses.
The outlook remains challenging with fuel cost volatility and competitive pressure from alternative aerospace investments. While travel demand provides some support, the ETF's concentration on airline operators exposes investors to cyclical industry risks and margin compression from elevated fuel expenses. Near-term performance depends on fuel price stabilization and geopolitical developments.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
